August 26, 2015 07:57 AM Eastern Daylight Time
SAN DIEGO--(BUSINESS WIRE)--Allele Biotechnology & Pharmaceuticals Inc., a San Diego based life sciences company with a focus on novel technology development, releases the first group of a brand new class of antibodies against crucial biological targets to the research market. This week, Allele launches nano-antibodies isolated from llamas against human bFGF, P16, VEGF, and TNFa, which are all important targets in the field of cancer biology.
Explora BioLabs will be opening its new preclinical contract research headquarters and fourth vivarium incubator facility in the Coast 9 complex in Sorrento Valley in mid-September. Together with its three other facilities in Torrey Pines Mesa and Mission Bay, Explora will now operate 40,000 square feet of small animal research space. Explora looks forward to using its expanded capacity to better serve San Diego’s vibrant entrepreneurial biotech community in moving their pharmacology programs forward. If you would like an invitation to Explora’s Sorrento Valley facility Grand Opening celebration or a tour of our new vivarium, please contact CEO Richard Lin at firstname.lastname@example.org.
ACD will soon be releasing our 100th cell-based protein tyrosine kinase assay and we invite you to share in the celebration! Our assay platform reveals kinase biologies that can go undetected using more traditional biochemical assays.
We want you to learn more about our system and invite you to participate in our upcoming webinar titled “Exploring the impact of genetically-altered kinases on small-molecule efficacy”.Read more
July 1, 2015. Orphagen Pharmaceuticals announced today that the National Institutes of Health (NIH) National Cancer Institute (NCI) has awarded the company $224,954 under the Small Business Innovative Research (SBIR) program to identify small molecule antagonist ligands for an novel drug discovery target for cancer immunotherapy. Orphagen proposes to find drug-like molecules to a previously unexplored orphan drug target that normally suppresses the immune response.
“We believe there is an opportunity to identify small molecule ligands to this orphan drug target. The ligands will enhance T cell activation and thus stimulate anti-tumor responses by enhancing the ongoing immune surveillance that already occurs in cancer patients.” said Dr. Haiyan Tao, Scientist and Principal Investigator of the grant. The drug-like molecules identified from this project would create a powerful and potentially safer therapeutic tool to enhance clinical cancer immunotherapy and improve patient survival.
Orphagen is a first-mover in the identification of small molecule compounds to three orphan nuclear receptors. Support from the NIH is a critical part of the Company’s overall strategy to discover new classes of drugs and commercialize them through partnerships.
DUBLIN, Ohio – June 30, 2015 – Cardinal Health Specialty Solutions has been selected to provide regulatory support to the National Center for Advancing Translational Sciences (NCATS) for its Therapeutics for Rare and Neglected Diseases (TRND) program under a research subcontract with Leidos Biomedical Research, Inc. (Leidos Biomed). NCATS is part of the National Institutes of Health (NIH).Read more
Molecular Diagnostics Consulting (MDxC) signed a Mutual Referral Agreement with Business Development Connections (BDC, Greenbrae, CA). MDxC specializes in providing diagnostic R&D guidance to start-up biotech, medical device, digital health and pharmaceutical companies developing FDA, LDT and RUO products. BDC provides business development support in the life sciences industry to contract research organizations (CROs), contract manufacturing organizations (CMOs) and consulting firms by identifying their outsourcing needs then connecting clients with qualified companies and consultants within BDC’s network. "Molecular Diagnostics Consulting is looking forward to growing our business through a mutually rewarding strategic relationship with BDC" - Sylvia A Norman, PhD, Founder & Principal Consultant at Molecular Diagnostics Consulting
Collaborative Drug Discovery received a $1.5M Phase 2 SBIR grant to develop their Bioassay Ontology Annotator software. A prototype of this software was successfully developed by CDD using a previously awarded Phase I SBIR grant.
The Bioassay Ontology Annotator, a tool to quickly annotate bioassay data, will be the foundation for a collaborative CDD electronic laboratory notebook (ELN). "With this grant we can now build automated annotation technologies into our platform that will advance the utility of applications like ELNs for secure collaboration and analyses.” said Barry A. Bunin, PhD, CDD CEO.
One World Lab entered an agreement with OriGene Technologies, Inc to become a global distributor of OriGene's antibody portfolio. "The addition of OriGene’s proprietary antibodies supports our strategy and broadens our portfolio to more than 75,000 unique antibodies. Researchers will have several thousand more antibodies to affordably sample, while knowing with confidence that each antibody is sourced from the original manufacturer and not re-labeled.Read more